Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents

Authors: Nuttall S.D.; Iring R.A.; Hudson P.J.

Source: Current Pharmaceutical Biotechnology, Volume 1, Number 3, November 2000 , pp. 253-263(11)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.

Keywords: Immunoglobulin VH Domains; Fv fragments; Recombinant single chain; Natural VH Domains; Camelidae; Camelisation

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201003378906

Publication date: 2000-11-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.